Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.

Jean-David FumetEmilie LardenoisIsabelle L Ray-CoquardPhilipp HarterFlorence JolyUlrich CanzlerCaroline TruntzerOlivier TredanClemens LiebrichAlain LortholaryDaniel PissalouxAlexandra LearyJacobus PfistererAlexandre EeckhoutteFelix HilpertMichel FabbroChristophe CauxJérôme AlexandreAurélie HoulierJalid SehouliEmilie SohierRainer KimmigBertrand DuboisDominique SpaethIsabelle TreilleuxJean-Sébastien FrenelUwe HerwigOlivia Le SauxNathalie Bendriss-Vermare Andreas du Bois

Published in: Cancers (2022)

Our results suggest HLA-E/CD94-NKG2A/2C is a potential immune target particularly in the HRD positive ovarian carcinoma subgroup.

Keyphrases

phase iii
nk cells
open label
clinical trial
study protocol
phase ii
copy number
placebo controlled
natural killer cells
human health
randomized controlled trial
gene expression
risk assessment
dna methylation
genome wide